OZO-H is a GST inhibitor. OZO-H is an OZO derivative with potent anti-cancer effects. OZO-H releases JNK1 from GST-JNK1 complex. OZO-H induces JNK1 phosphorylation and activates c-Jun in cancer cells.

OZO-Cl is an OZO derivative. OZO-Cl has anti-cancer activity. OZO-Cl significantly decreases the intracellular glutathion S-transferase Pi (GST) activity. OZO-Cl exhibits cytotoxicity to cancer cell lines, with IC50s of 150 and 120 μmol/L in Panc-1 and K562 cells respectively.

BO 1341 is a PBPs inhibitor and an antipseudomonal semisynthetic cephalosporin. BO 1341 exhibits antibacterial activity against most Gram-negative bacteria, such as Pseudomonas aeruginosa (MIC90: 1.56 μg/mL), Pseudomonas maltophilia (MIC50: 1.56 μg/mL), and Acinetobacter calcoaceticus (MIC90: 3.13 μg/mL) . BO 1341 can be used in the research of infectious diseases.

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins.

ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa.

Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nucresiran sodium is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nivudirsen is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

Nivudirsen sodium is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

FBnG-amino-PEG3-C2-azido is a tag-linker conjugate that incorporates a degradation tag FBnG and a glycol linker (Amino-PEG3-C2-Azido). FBnG-amino-PEG3-C2-azido can be used for synthesis of GPX4-AUTAC

Duazomycin (Duazomycin A) sodium is a glutamine antagonist. Duazomycin sodium can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.

Movronersen is an antisense oligonucleotide targeted to α-synuclein.

Movronersen sodium is an antisense oligonucleotide targeted to α-synuclein.

Mivelsiran is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

Mivelsiran sodium is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

Lufepirsen is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lufepirsen sodium is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lixadesiran is a siRNA in STP705. It targets to COX-2. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Lixadesiran sodium is a siRNA in STP705. It targets to COX-2. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Litenimod is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

(-)-Luteoskyrin has a wide range of antibacterial activity, such as against malaria (with an IC50 of 0.51 μg/mL), tuberculosis (MIC of 6.25 μg/mL), and it also shows antibacterial effects (with MIC for Gram-positive bacteria ranging from 0.39 to 1.56 μg/mL, and for Gram-negative bacteria from 3.13 to 12.50 μg/mL), as well as antifungal activity (with MIC against plant pathogens ranging from 3.13 to 50μg/mL). (-)-Luteoskyrin exhibits cytotoxicity against NCI-H187 cells, with an IC50 range of 0.16–17.99 μg/mL.

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

TL13-12 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of TAE684 and the cereblon ligand pomalidomide.

dBET57 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM), but is inactive on BRD4 BD2..

N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.

GK420 (AVX420) is a potent inhibitor of cytosolic phospholipase A2α (cPLA2α), with the XI(50) of 0.0016. GK420 inhibits arachidonic acid release with the EC50 of 0.09 μM. GK420 plays an important role in cancer research.

S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.